hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease

• Status: Withdrawn
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The human immune system produces a protein called hCAP18 (also known as LL-37 or cathelicidin). This protein is believed to help the body to fight infections. Studies suggest that vitamin D may important in the production of hCAP18. This study is designed to test the ability of two different forms of vitamin D to affect levels of hCAP18. Vitamin D and hCAP18 levels will be measured during an initial visit. Individuals who are vitamin D deficient will be randomly assigned to receive one of two forms of vitamin D for two weeks. After this, follow-up levels will be measured.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Kidney Foundation
• Treatments: Calcitriol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Age 18-80

• Chronic Kidney Disease stage 3-4 (estimated glomerular filtration rate 15-60 ml/min)

Exclusion Criteria:

• 6 month history of hypercalcemia, hyperphosphatemia, or nephrolithiasis

• use of active vitamin D analog within 30 days

• functioning renal transplant

• Symptoms of active infection

• Granulomatous disorders